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ABSTRACT
Breast cancer is the most common female cancer, affecting approximately one in 
eight women during their lifetime in North America and Europe. Receptor Activator of 
NF-kB Ligand (RANKL), its receptor RANK and the natural antagonist osteoprotegerin 
(OPG) are essential regulators of bone resorption. We have initially shown that 
RANKL/RANK are essential for hormone-driven mammary epithelial proliferation in 
pregnancy and RANKL/RANK have been implicated in mammary stem cell biology. 
Using genetic mouse-models, we and others identified the RANKL/RANK system 
as a key regulator of sex hormone, BRCA1-mutation, and oncogene-driven breast 
cancer and we proposed that RANKL/RANK might be involved in the initiation of 
breast tumors. We now report that in postmenopausal women without known genetic 
predisposition, high RANKL and progesterone serum levels stratify a subpopulation of 
women at high risk of developing breast cancer 12-24 months before diagnosis (5.33-
fold risk, 95%CI 1.5-25.4; P=0.02). In women with established breast cancer, we 
demonstrate that RANKL/OPG ratios change dependent on the presence of circulating 
tumor cells (CTCs). Finally, we show in a prospective human breast cancer cohort 
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INTRODUCTION
RANKL (receptor activator of NF-kB ligand), its 
receptor RANK, and the decoy receptor osteoprotegerin 
(OPG) are essential for the development and activation 
of osteoclasts [1, 2]. Based on these findings, RANKL 
inhibition with a fully human, blocking monoclonal 
antibody (Denosumab) has been developed as a novel and 
rational therapy against osteoporosis and skeletal related 
events in cancer patients [3-7]. RANKL/RANK also 
control lymph node organogenesis and the development of 
thymic medullary epithelial cells [1, 8, 9]. In addition, we 
have previously shown that the RANKL/RANK system 
is essential for the formation of a lactating mammary 
gland during pregnancy [10, 11] indicating that RANKL/
RANK play a role in normal mammary gland biology and 
hormone-driven epithelial proliferation. Indeed, using 
genetic mouse-models, our group and Gonzalez-Suarez et 
al. have identified the RANKL/RANK system as a key 
regulator of hormone (progestin) and oncogene (Neu)-
driven breast cancer [12, 13]. Moreover, we [14] and 
others [15] have recently reported that RANKL/RANK 
also control breast cancer development in scenarios of 
BRCA1 mutations. Mechanistically, RANKL/RANK 
promote the proliferation of human and mouse mammary 
gland epithelial cells, protect these cells from apoptotic 
cell death after DNA damage, control tumor stem cell 
renewal, and might have a role in basic mammary stem 
cell biology [12-18]. Furthermore, RANKL/RANK have 
also been implicated in metastases [12, 13, 19, 20]. 
Breast cancer is the most common female cancer, 
affecting approximately one in eight women during 
their life-time in North America and Europe [21, 22]. 
Identifying a biomarker which serves as both an indicator 
for breast cancer risk and at the same time a possible 
target for prevention is one of the most important yet 
unsolved needs. RANKL is expressed in primary breast 
cancers in patients and human breast cancer cells lines 
[14-19, 23] and, in mouse studies, the RANKL/RANK 
system is an important molecular link between progestins 
and oncogene-driven epithelial carcinogenesis [12, 13]. 
We therefore hypothesized that serum levels of RANKL 
and OPG could serve as markers for breast cancer risk 
providing a molecular rationale for future breast cancer 
prevention. 
RESULTS
High serum levels of RANKL and progesterone 
stratify a subpopulation of women at increased 
risk of developing breast cancer
In order to test whether deregulation of the RANKL/
OPG system is associated with breast cancer in women 
without known genetic predispositions, we analyzed 
serum levels in postmenopausal women participating in 
the prospective UKCTOCS (UK Collaborative Trial of 
Ovarian Cancer Screening) study [24, 25] (Table 1). This 
cohort of women provided a unique opportunity to study 
changes in serum levels of soluble RANKL and OPG well 
in advance of breast cancer manifestation. A total of 278 
samples from postmenopausal women were analyzed: 40 
women donated a serum sample between 5 and 12 months 
prior to breast cancer diagnosis (median age at sample 
taken 64.84), 58 women provided sera between 12 and 
24 months prior to breast cancer diagnosis (median age at 
sample taken 60.49 years) and 180 women, who did not 
develop breast cancer during their follow up (median age 
at sample taken 62.94 years), served as controls. 
We did not observe significant differences in 
RANKL, OPG or RANKL-to-OPG ratios in controls and 
women who developed breast cancer 12-24 months after 
serum sampling (Figure 1A-1C). Since we have previously 
shown that RANKL mediates progesterone driven 
mammary epithelial proliferation [12] and the RANKL/
RANK system is a key mediator of progestin-driven breast 
cancer in mouse models [12, 13], we explored a potential 
connection between progesterone and RANKL/OPG 
levels in humans. Intriguingly, we observed an increase of 
RANKL serum levels with increasing progesterone levels 
in women who developed breast cancer 12-24 months 
after sample collection (Figure 2A) and the opposite 
trend in controls. In the same cohort, we also observed a 
non-significant negative correlation of progesterone with 
OPG serum levels (Figure 2B) resulting in a significant 
alteration in the RANKL/OPG ratio among women with 
high serum progesterone (Figure 2C). 
To assess whether high progesterone and high 
RANKL indeed define a subgroup of women with 
increased risk of developing breast cancer, we classified 
all women - cases and controls considered together - into 
that alterations in RANKL/OPG ratios are significantly associated with breast cancer 
manifestation. These data indicate that the RANKL/RANK/OPG system is deregulated 
in post-menopausal women at high risk for breast cancer and in women with circulating 
tumor cells. Thus, serum levels of RANKL/OPG are potentially indicative of predisposition 
and progression of breast cancer in humans. Advancement of our findings towards clinical 
application awaits prior validation in independent patient cohorts. 
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tertiles according to their serum progesterone levels. 
Within each group women were classified into low, 
medium or high RANKL, OPG and RANKL/OPG based 
on controls within the corresponding progesterone group. 
Using logistic regression women with high progesterone 
and high RANKL exhibited a 4.8 (95% CI 1.3 - 22.8; p 
= 0.0269) fold risk (Table 2). OPG levels alone did not 
modify the risk (Table 3). Importantly, women within the 
high progesterone and high serum RANKL/OPG ratio 
group carried a 5.3 (95% CI 1.5 - 25.4, p = 0.0169) fold 
risk to develop breast cancer 12-24 months after diagnosis 
(Table 4). We also grouped the women into RANKL/
OPG tertiles across all controls (not only within a given 
progesterone tertile) and again women within the high 
progesterone/high RANKL/OPG group had a 4.2 (95% CI 
1.3 - 16.0, p = 0.02) fold risk for developing breast cancer. 
Thus, high serum levels of RANKL and high serum 
progesterone stratify a subpopulation of postmenopausal 
Table 1: Clinicopathological features of women who developed invasive breast cancer 
within the UKCTOCS trial 5 to 24 months after they provided their serum sample.
Clinicopathological Characteristics
Breast Cancer Diagnosis after
5-12mo 12-24mo
(n = 40) (n = 58)
Histology Classification   
IDC 27 48
ILC 9 9
ITC 1 0
Other 1 1
Unknown 2 0
Stage (TNM)  
1 21 29
2 3 14
3 1 2
Unknown 15 13
Grade   
I 9 9
II 24 29
III 7 20
Hormone receptor status  
ER positive 40 58
PR negative 8 22
PR positive 20 8
PR unknown 12 28
HER2  
HER2 negative 15 17
HER2 positive 4 4
Unknown 21 37
Nodal Status  
Positive 7 13
Negative 33 45
*IDC, invasive ductal cancer; ILC, invasive lobular cancer; ITC, invasive tubular cancer.
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Table 2. Association of serum progesterone and RANKL with risk of breast cancer. 
Progesterone LOW (range  0.03 - 0.19 ng/ml)*           
RANKL [pmol/l] Controls Breast Cancer < 12 months Breast Cancer > 12 months
Tertile$ Range N (%) N (%) OR (95% CI)¶ P-value N (%) OR (95% CI)¶ P-value
1st 0.003 0.0193 21 33.9 7 50.0 1(ref)  6 42.9 1(ref)  
2nd 0.0193 0.179 20 32.3 4 28.6 0.60 0.1 2.3 0.47 8 57.1 1.40 0.4 4.9 0.59
3rd 0.179 3.716 21 33.9 3 21.4 0.43 0.1 1.8 0.26 0 0.0 0.00 NA  0.99
Progesterone MEDIUM (range 0.19 - 0.31 ng/ml)*          
RANKL [pmol/l] Controls Breast Cancer < 12 months Breast Cancer > 12 months
Tertile$ Range N (%) N (%) OR (95% CI)¶ P-value N (%) OR (95% CI)¶ P-value
1st 0.004 0.0255 18 32.1 6 60.0 1(ref)  8 34.8 1(ref)  
2nd 0.0255 0.1745 19 33.9 3 30.0 0.47 0.1 2.1 0.34 9 39.1 1.07 0.3 3.4 0.91
3rd 0.1745 1.5235 19 33.9 1 10.0 0.16 0.0 1.0 0.10 6 26.1 0.71 0.2 2.4 0.59
Progesterone HIGH (0.31 - 12.68 ng/ml)*           
RANKL [pmol/l] Controls Breast Cancer < 12 months Breast Cancer > 12 months
Tertile$ Range N (%) N (%) OR (95% CI)¶ P-value N (%) OR (95% CI)¶ P-value
1st 0.0045 0.0135 20 32.3 5 31.3 1(ref)  3 14.3 1(ref)  
2nd 0.0135 0.0675 21 33.9 5 31.3 0.95 0.2 3.9 0.94 3 14.3 0.95 0.2 5.7 0.96
3rd 0.0675 1.2315 21 33.9 6 37.5 1.14 0.3 4.5 0.84 15 71.4 4.76 1.3 22.8 0.03
* All women - cases and controls considered together – were classified into tertiles according to their serum progesterone 
levels. 
$ Within each group, women were classified into low, medium or high RANKL based on controls within the corresponding 
progesterone group. 
¶ Using logistic regression odd ratios (ORs) and 95% Confidence Intervals (CI) have been calculated using the lowest RANKL 
group as a reference. Cases have been considered separately according to the time to diagnosis (more than one year or less).
Table 3: Association of serum progesterone and OPG with risk of breast cancer. 
Progesterone LOW (range  0.03 - 0.19 ng/ml)*           
OPG [pmol/l] Controls Breast Cancer < 12 months Breast Cancer > 12 months
Tertile$ Range N (%) N (%) OR (95% CI)¶ P-value N (%) OR (95% CI)¶ P-value
1st 1.2685 2.0267 21 33.9 1 7.1 0.33 0.0 2.8 0.36 6 42.9 0.86 0.2 3.0 0.81
2nd 2.0267 2.9685 20 32.3 10 71.4 3.50 0.9 17.3 0.09 1 7.1 0.15 0.0 1.0 0.09
3rd 2.9685 4.917 21 33.9 3 21.4 1(ref)    7 50.0 1(ref)    
Progesterone MEDIUM (range 0.19 - 0.31 ng/ml)*          
OPG [pmol/l] Controls Breast Cancer < 12 months Breast Cancer > 12 months
Tertile$ Range N (%) N (%) OR (95% CI)¶ P-value N (%) OR (95% CI)¶ P-value
1st 0.8385 1.8617 19 33.9 2 20.0 0.40 0.1 2.1 0.31 7 30.4 0.88 0.3 2.9 0.83
2nd 1.8617 2.7008 18 32.1 3 30.0 0.63 0.1 3.0 0.57 8 34.8 1.06 0.3 3.5 0.93
3rd 2.7008 4.9335 19 33.9 5 50.0 1(ref)    8 34.8 1(ref)    
Progesterone HIGH (0.31 - 12.68 ng/ml)*           
OPG [pmol/l] Controls Breast Cancer < 12 months Breast Cancer > 12 months
Tertile$ Range N (%) N (%) OR (95% CI)¶ P-value N (%) OR (95% CI)¶ P-value
1st 0.6015 2.0855 21 33.9 4 25.0 0.40 0.1 1.4 0.17 10 47.6 2.00 0.6 7.4 0.27
2nd 2.0855 2.9933 20 32.3 2 12.5 0.21 0.0 0.9 0.06 6 28.6 1.26 0.3 5.0 0.73
3rd 2.9933 9.9125 21 33.9 10 62.5 1(ref)    5 23.8 1(ref)    
* All women - cases and controls considered together – were classified into tertiles according to their serum progesterone levels. 
$ Within each group, women were classified into low, medium or high OPG based on controls within the corresponding progesterone group. 
¶ Using logistic regression odd ratios (ORs) and 95% Confidence Intervals (CI) have been calculated using the highest OPG group as a 
reference. Cases have been considered separately according to the time to diagnosis (more than one year or less).
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women without known genetic predisposition at high 
risk of developing breast cancer 12-24 months before 
diagnosis. 
RANKL/OPG levels in females close to onset of 
breast cancer diagnosis and cancer patients with 
circulating tumor cells
We next analyzed the group of UKCTOCS 
participants who developed breast cancer within 12 
months (BC < 12 months). However, among this cohort 
high progesterone/high RANKL levels were not associated 
with an increased incidence of breast cancer (Figure 2, 
Table 4). Intriguingly, we rather observed a progesterone-
independent reduction in RANKL and increase in OPG 
serum levels with breast cancer manifestation resulting 
in significant decrease in the RANKL-to-OPG ratio 
compared to UKCTOCS participants who never developed 
breast cancer (Figure 3A). These results indicate that 
RANKL levels drop whereas OPG levels increase in 
women close to clinical manifestation of breast tumors. 
One possible explanation for this phenomenon could be 
that some women already harbor subclinical disseminated 
tumor cells that could lead to the observed alterations in 
serum RANKL/OPG. 
To test this hypothesis, we analysed serum RANKL/
OPG in women with breast cancer diagnosis but in the 
absence of a tumor in the breast - a similar scenario as in 
the UKCTOCS cohort close to breast cancer diagnosis. We 
analyzed 116 ER positive breast cancer patients from the 
SUCCESS trial after surgery and before systemic therapy 
(Table 5). Figure 3B demonstrates serum RANKL/OPG 
levels stratified to the number of circulating tumor cells 
(CTCs) identified in the corresponding blood sample 
[26, 27]. Intriguingly, women with a small number of 
CTCs (1-2 CTCs) exhibited a significantly reduced 
serum RANKL/OPG ratio compared to women without 
detectable CTCs (Figure 3B). Women with a 3-5 CTCs 
also exhibited reduced serum RANKL/OPG ratios, though 
this reduction did not reach statistical significance. Of 
note, the serum RANKL/OPG ratio tends to increase again 
with an increase in CTCs, albeit the numbers of cases is 
too small to allow for a firm conclusion. Thus, women 
with a very low number of CTCs in their blood exhibit a 
reduced RANKL/OPG ratio suggesting that the alterations 
we find up to one year in advance of a clinical breast 
cancer indeed correlate with low numbers of disseminated 
breast cancer cells. 
Confirmation of altered RANKL/OPG ratios in 
an independent prospective breast cancer cohort
To substantiate these data in another entirely 
independent cohort, we determined RANKL and OPG 
serum levels of participants from the Bruneck study [28, 
29], that allowed us to analyse matched patient samples 
Figure 1: RANKL/OPG ratios are not changed in women that develop breast cancer within 12-24 month after serum 
sampling. A.-C. Analysis of individual RANKL and OPG levels in prospectively collected serum samples from UKCTOCS (UK 
Collaborative Trial of Ovarian Cancer Screening) from 180 healthy postmenopausal women who did not develop breast cancer during their 
follow up and 58 healthy age-matched women who did develop estrogen receptor positive breast cancer 12-24 months after their serum was 
collected. Box plots of RANKL A., OPG B. levels as well as RANKL-to-OPG ratios C. are shown. There were no significant differences 
(Mann Whitney U test). Box plots indicate median ratio levels and inter-quartile ranges. 
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Figure 2: RANKL/OPG serum levels in human breast cancer patients. Analysis of RANKL A., OPG B. and the ratio RANKL/
OPG C. in relation to progesterone levels in prospectively collected UKCTOCS serum samples from 180 healthy postmenopausal women 
who did not develop breast cancer during their follow up and 40 healthy age-matched women who developed estrogen receptor positive 
breast cancer 5-12 months after their serum was collected as well as 58 healthy age-matched women who did develop ER-positive breast 
cancer 12-24 months after their serum was collected. Women were grouped according to their serum progesterone levels. Subjects were 
stratified into breast cancer patients and controls due to self reporting and histological examination. We have tested differences in RANKL, 
OPG and RANKL/OPG within each group between low versus medium and medium versus high progesterone within each group using the 
Mann Whitney U test and displayed only the significant p-values (p < 0.05).
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before and after cancer manifestation. Of 821 subjects 
with two or more sequential measurements of RANKL 
and OPG, 697 subjects remained free of cancer during the 
15-year follow-up, 19 women developed breast cancer, 16 
men developed prostate cancer, and 89 other cancer types 
(all malignancies except for squamous-cell skin cancer). In 
line with the UKCTOCS study, levels of RANKL declined 
with the manifestation of breast cancer (p = 0.006; paired 
t-test), whereas RANKL serum concentrations were not 
altered in subjects with other types of new-onset cancer 
and those remaining free of neoplastic disease (Figure 
4A). In parallel, OPG levels rose with the diagnosis of 
breast cancer (p = 0.037; paired t-test), whereas no such 
increase was observed in patients with other types of 
cancer or subjects free of neoplastic disease (Figure 4A). 
As a consequence, the RANKL-to-OPG ratio significantly 
decreased in individuals with new-onset breast cancer 
(Figure 4B). In males, no significant differences in OPG 
Figure 3: Alterations in RANKL/OPG levels in females close to onset and after manifestation of breast cancer. A. 
Analysis of OPG, RANKL, and RANKL/OPG ratios in prospectively collected UKCTOCS serum samples from 180 healthy postmenopausal 
women who did not develop breast cancer during their follow up (control) and 40 healthy age-matched women who developed ER positive 
breast cancer 5-12 months after their serum was collected. P values were calculated using a Mann Whitney U test. B. Analysis of RANKL/
OPG ratios in 116 women in the SUCCESS trial after resection of the local ER positive breast cancer and before start of systemic treatment 
based on the numbers of CTCs. P values were calculated using the Mann Whitney U test. Abbreviations: CTC, circulating tumor cell; ER, 
estrogen receptor; OPG, osteoprotegerin; RANKL, Receptor Activator of NF-kB ligand. 
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and RANKL levels were found in cancer-free individuals 
or those with new onset prostate cancer, which is also 
related to sex hormones, or other types of cancer (Figures 
5A, 5B). Our data in two different human prospective 
breast cancer cohorts indicate that alterations in RANKL/
OPG ratios are significantly associated with breast cancer 
manifestation.
DISCUSSION
We and other groups have previously demonstrated 
a central role for the osteoclastogenic molecule 
RANKL in breast cancer development using genetic 
mouse models [12-15]. Here we show that increased 
progesterone and RANKL serum levels stratify a subgroup 
of postmenopausal women without known genetic 
predispositions that exhibit a ~5 fold increased risk of 
developing breast cancer 12-24 months before cancer 
diagnosis. This indicates that either increased free RANKL 
or high RANKL and high progesterone serum levels, as 
seen in the case of our postmenopausal UK cohort, could 
be useful biomarkers to predict future breast cancer more 
than one year in advance of breast cancer diagnosis. These 
data are in line with our genetic mouse models that the 
RANKL/RANK/OPG system drives the initiation and 
progression of breast cancer [12-15]. Our findings that 
an increased RANKL/OPG ratio > 12 months prior to 
breast cancer development is consistent with findings 
from meta-analysis by Key et al. that showed that sex 
steroid hormone levels well in advance of breast cancer 
diagnosis are more significantly associated with breast 
cancer risk compared with hormone levels analyzed closer 
to diagnosis [30]. 
When we analyzed the serum of postmenopausal 
women shortly before breast cancer diagnosis or matched 
sera from women before and after clinical manifest breast 
cancer, we observed reduced RANKL and increased 
OPG serum levels. A similar phenomenon was shown 
for serum RANKL levels and osteoporosis: low serum 
RANKL levels are associated with a 10-fold higher risk of 
non-traumatic fractures in postmenopausal women [31]. 
Moreover, increased OPG is associated with enhanced 
bone loss in postmenopausal women not on hormone 
replacement therapy [32] and increased OPG levels have 
been observed in patients with bone metastasis [33]. The 
mechanisms of these serum changes in breast cancer need 
to be further investigated and might reflect compensatory 
mechanisms against developing microtumors and/or 
redistribution/sequestration of RANKL/OPG within 
different body compartments. Although women in our 
Table 4: Association of serum progesterone and RANKL/OPG ratio with risk of breast cancer.  
Progesterone LOW (range  0.03 - 0.19 ng/ml)*          
RANKL/OPG ratio Controls Breast Cancer < 12 months Breast Cancer > 12 months
Tertile$ Range N (%) N (%) OR (95% CI)¶ P-value N (%) OR (95% CI)¶ P-value
1st 0.0014 0.0075 21 33.9 7 50.0 1(ref)  9 64.3 1(ref)  
2nd 0.0075 0.0644 20 32.3 4 28.6 0.60 0.1 2.3 0.47 5 35.7 0.58 0.2 2.0 0.40
3rd 0.0644 2.0472 21 33.9 3 21.4 0.43 0.1 1.8 0.26 0 0.0 0.00 NA NA 1.0
Progesterone MEDIUM (range 0.19 - 0.31 ng/ml)*          
RANKL/OPG ratio Controls Breast Cancer < 12 months Breast Cancer > 12 months
Tertile$ Range N (%) N (%) OR (95% CI)¶ P-value N (%) OR (95% CI)¶ P-value
1st 0.0017 0.0154 19 33.9 6 60.0 1(ref)  8 34.8 1(ref)  
2nd 0.0154 0.091 18 32.1 4 40.0 0.70 0.2 2.9 0.63 9 39.1 1.19 0.4 3.8 0.77
3rd 0.091 0.4605 19 33.9 0 0.0 0.00 NA  0.99 6 26.1 0.75 0.2 2.6 0.65
Progesterone HIGH (0.31 - 12.68 ng/ml)*           
RANKL/OPG ratio Controls Breast Cancer < 12 months Breast Cancer > 12 months
Tertile$ Range N (%) N (%) OR (95% CI)¶ P-value N (%) OR (95% CI)¶ P-value
1st 0.0015 0.0057 21 33.9 6 37.5 1(ref)  3 14.3 1(ref)  
2nd 0.0057 0.0245 20 32.3 4 25.0 0.70 0.2 2.8 0.62 2 9.5 0.70 0.1 4.7 0.71
3rd 0.0245 0.4672 21 33.9 6 37.5 1.00 0.3 3.7 1.00 16 76.2 5.33 1.5 25.4 0.02
* All women - cases and controls considered together – were classified into tertiles according to their serum progesterone 
levels.
$ Within each progesterone tertile, women were classified into low, medium or high RANKL/OPG based on controls within 
the corresponding progesterone group.
¶ Using logistic regression odd ratios (ORs) and 95% Confidence Intervals (CI) have been calculated using the lowest 
RANKL/OPG group as a reference. Cases have been considered separately according to the time to diagnosis (more than one 
year or less).
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study do not have clinical manifest bone metastasis, it 
has been demonstrated that tumor cells can disseminate 
systemically from earliest epithelial alterations in 
transgenic mice and even from very early breast cancers in 
women and that these disseminated tumor cells can form 
micrometastasis in bone marrow and lungs [34]. Likewise, 
it is well established that breast cancer cells interfere with 
osteoblasts (being a major source for RANKL) and induce 
osteoblast necrosis and apoptosis [35]. Hence the effect 
we see on RANKL and the RANKL/OPG ratio in women 
who get clinical manifest breast cancer close to serum 
collection may be triggered by an effect of epithelial/tumor 
Figure 4: Alterations in RANKL/RANKL levels in females close to onset and after breast cancer. A. Individual changes 
in serum levels of OPG and soluble RANKL in 19 female subjects from our longitudinal Bruneck cohort before and after manifestations 
of breast cancer (dotted black lines). Mean changes are shown for subjects with incident breast cancer (red lines), other types of new-onset 
cancer (n = 32; green lines) and women free of neoplastic disease during the 15 year follow-up (n = 360; black lines). B. Box plots of 
RANKL-to-OPG ratios assessed prior to and after cancer manifestation in women from the prospective Bruneck study indicate median 
ratio levels and inter-quartile ranges. In individuals who remained free of cancer, ratios given are those assessed at the time intervals 
corresponding to those in cancer patients. 
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cells altering RANKL/OPG in the bone marrow.  Of note, recently it has been reported that blocking of RANKL 
Figure 5: No changes in RANKL/OPG ratios in man that develop prostate cancer or females with non-breast cancer. 
A. Individual changes in serum levels of osteoprotegerin (OPG) and soluble (s) RANKL in 16 male subjects from our longitudinal Bruneck 
cohort before and after manifestations of prostate cancer (dotted black lines). Mean changes are shown for subjects with incident prostate 
cancer (red lines), other types of new-onset cancer (n = 57; green lines) and men free of neoplastic disease during the 15 year follow-up (n 
= 337; black lines).B. Box plots of RANKL-to-OPG ratios indicate median ratio levels and inter-quartile ranges. Data were assessed prior 
to and after prostate cancer manifestation, males with other types of new-onset cancer and men free of neoplastic disease during the 15 
year follow-up. For individuals who remained free of cancer, ratios given are those assessed at the time intervals corresponding to those in 
cancer patients.
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reduces the reoccurrence of breast cancer in women 
receiving adjuvant Tamoxifen therapy [36]. 
One key issue for the management of cancer is 
to accurately predict the risk in order to triage women 
into screening or preventive strategies. In breast cancer, 
population-based mammography screening is currently 
used to identify women with early breast cancer. Our data 
suggest that the apparent alterations in RANKL/OPG in 
postmenopausal women with high progesterone levels 
could be used as a future biomarker to identify a subgroup 
of women at high risk of breast cancer. Moreover, it 
has been recently shown that women with high genetic 
breast cancer risk due to BRCA1 mutations appear to be 
exposed to increased RANKL [37]. Our data also indicate 
that serum RANKL/OPG ratios correlate with CTCs and 
that a low number of CTCs - even in the absence of a 
local breast cancer - is associated with a reduced serum 
RANKL/OPG ratio. The mechanism of this phenomenon 
is not yet clear, but it is attractive to speculate that 
unknown soluble serum factors which are associated with 
a low number of CTCs may suppress RANKL expression 
and/or alter processing of membrane bound RANKL into 
soluble RANKL. These studies now need to be confirmed 
in additional cohorts. Since an antibody to block RANKL 
(Denosumab) has already been approved for treatment 
of osteoporosis patients and treatment of skeletal related 
events in solid tumors [3, 7], our data in the presented 
prospective human cohorts further support the notion that 
the same antibody could potentially be used to prevent 
the development of breast cancer in high risk women. 
Advancement of our findings towards clinical application 
awaits prior validation in independent patient cohorts. 
MATERIALS AND METHODS
UK collaborative trial of ovarian cancer screening 
(UKCTOCS)
The first group of subjects were participants in the 
UK Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) [24, 25], a multi-centre randomized 
controlled trial of ovarian cancer screening that has 
recruited 202,638 postmenopausal women. The trial was 
set up at 13 National Health Services (NHS) trusts in 
England, Wales and Northern Ireland and is coordinated 
by the Gynecological Cancer Research Centre at the 
University College London (UCL). Women aged 50-
74 were recruited through random invitation from age/
sex registers of 27 participating Primary Care Trusts. At 
recruitment, written consent was obtained which included 
access to their medical records and use of their data/
samples in future secondary studies. UKCTOCS was 
approved by the UK North West Multicentre Research 
Ethics Committees (North West MREC 00/8/34). Women 
were randomized in a 2:1:1 ratio to (1) a control group 
with no intervention (101 359 women), (2) a multimodal 
group with annual screening with CA125 (50 640 women) 
and (3) an ultrasound group with annual screening with 
ultrasound (50 639 women). Eligibility criteria included 
(a) age between 50 and 74 years and (b) postmenopausal 
status defined as > 12 months amenorrhea following 
a natural or surgical menopause, or > 12 months of 
hormone replacement therapy commenced for menopausal 
symptoms. The exclusion criteria were: (a) history of 
bilateral oophorectomy, (b) active non-ovarian malignancy 
(women with a past history of malignancy were eligible if 
they had no documented persistent or recurrent disease), 
(c) increased risk of ovarian cancer because of familial 
predisposition and (d) previous history of ovarian cancer. 
All women are followed through the national cancer 
registries and follow-up postal questionnaires. For 
confirmation of diagnosis, their treating physician was 
sent a questionnaire requesting information regarding their 
diagnosis (histopathology) and treatment. UKCTOCS was 
approved by the UK North West Multicentre Research 
Ethics Committees (North West MREC 00/8/34). 
For the current study, eligible cases, who developed 
estrogen receptor positive invasive breast cancer after 
joining the trial being identified through the cancer 
Table 5: Clinicopathological features of the 116 ER 
positive SUCCESS patients.
Clinicopathological Characteristics
Histology Classification No
IDC 81
ILC 27
Other 8
Stage (T)
1 41
2 62
3 12
4 1
Grade  
I 3
II 76
III 37
HER2
positive 20
negative 96
CTC  
Present 59
Absent 57
Abbreviations: CTC, circulating tumor cells; ER, estrogen 
receptor; HER2, human epidermal growth factor receptor 
2; IDC invasive, ductal cancer; ILC, invasive lobular 
cancer.
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registries or self-reporting on follow-up questionnaire, 
donated a serum sample between 5 and 24 months 
prior to diagnosis (N = 98). Out of these 98 women 58 
women donated a sample between 12 and 24 months 
prior to diagnosis (median age at sample taken 60.49 
years) and 40 between 5 and 12 months (median age at 
sample taken 64.84). Eligible controls were matched 
UKCTOCS participants who had no history of breast 
cancer at last follow-up (median time between sample 
collection and follow up is 3.24 years) and had donated 
serum samples on the same day and in the same clinic 
(N = 180) as cases (median age at sample taken 62.94 
years). Clinicopathological data of the cases are provided 
in Table 1. Each breast cancer case was age-matched with 
two control women. Both cases and controls were not on 
hormone replacement therapy (HRT) at the time of sample 
collection. Blood samples were collected into Griener Bio 
one gel tubes (Cat no: 455071) at the centers, shipped 
overnight to the central laboratory and centrifuged at 
2000 g for 10 minutes. The serum was removed from the 
cells within 56 hours of sample collection and was frozen 
using a two stage freezing process: 12 hours at -80◦C and 
then placed in liquid nitrogen (vapor phase) -1 800◦C. A 
semi-automated system aliquoted serum in 500 µl straws 
which were then heat sealed, bar coded, and stored in 
liquid nitrogen tanks. One straw was retrieved and the 
samples were only thawed before use. Ethical approval 
for this nested case control study was obtained from the 
Joint UCL/UCLH Committees on the Ethics of Human 
Research (REC reference: 06/Q0505/102).
SUCCESS trial
Eligible patients were defined as women with 
histologically confirmed invasive breast cancer (stages 
pT1-4, pN0-3, M0) who had their tumors completely 
removed and agreed to participate in the randomized 
phase III SUCCESS A study. The main inclusion 
criterion was the indication for adjuvant chemotherapy 
defined by either positive axillary nodal status or node 
negative disease with additional factors associated with 
an increased risk for recurrence, i.e. pT ≥ 2, grade 3, 
age younger than 35 years or negative hormone receptor 
status. The SUCCESS A study compared the disease-
free survival after randomization in patients treated 
with 3 cycles of Epirubicin (100 mg/m²)-Fluorouracil 
(500 mg/m²)-Cyclophosphamide (500 mg/m², FEC) 
chemotherapy every three weeks (q3w) followed by 
3 cycles of Docetaxel (100 mg/mg², D) q3w versus 3 
cycles of FEC q3w followed by 3 cycles of Gemcitabine 
(1,000mg/m² d1,8)-Docetaxel (75 mg/m², DG) q3w. After 
chemotherapy, patients were randomized to receive two 
(q 3 months x 24 months) versus five years of zoledronate 
(q 3 months x 24 months followed by q 6 months x 36 
months). Women with hormone receptor positive disease 
received endocrine treatment. Premenopausal women 
received tamoxifen alone or in combination with goserelin 
for two years if they were younger than 40 years of age or 
became premenopausal within 6 months of chemotherapy. 
Hormone receptor positive postmenopausal patients 
were treated with tamoxifen for two years followed by 
anastrozole for three years. 2026 patients had a blood 
sample drawn after R0 resection of the primary tumor 
before the start of adjuvant chemotherapy. All blood 
samples were obtained after written informed consent. 
The study was approved by all responsible ethical boards 
and conducted in accordance with the Declaration of 
Helsinki. Ethics number: 076-05 (Ethical committee of 
the Ludwig Maximilian University of Munich). EudraCT 
Nr.: 2005-000490-21; Protocol ID: SUCCESS - Vorlage 
Nr.: 4030471. 
CTC analysis
CTCs [26, 27] were analyzed using the CellSearch 
System (Veridex, USA). Peripheral blood was drawn 
into three CellSave preservative tubes containing a 
cell stabilizing agent. The samples were shipped at 
room temperature to the central cancer immunological 
laboratory at the Women´s Hospital of the University 
of Munich Innenstadt and analyzed within 96 hours 
after arrival. Briefly, 30ml of blood was pooled and 
reduced to 7.5 ml by centrifugation of the sample for 10 
minutes at 800 x g. Plasma was removed and dilution 
buffer added and this mixture was overlaid over 6 ml 
of Histopaque using a syringe with valve and tubing, 
before another centrifugation step for 10 minutes at 400 
x g. Subsequently, 7.5 ml of this sample containing the 
buffy coat was processed automatically using a CellTracks 
AutoPrep System. The CellSearch Epithelial Cell Kit was 
used for CTC enrichment and enumeration. After immune-
magnetic enrichment with an anti-Epcam antibody bound 
to magnetic beads, cells were labeled with fluorescent anti-
cytokeratin (CK 8,18,19-phycoerythrin) and anti-CD45 
antibodies (CD45-allophycocyan) to distinguish between 
epithelial cells and leukocytes. The fluorescent nucleic 
acid dye 4,6-diamidino-2-phenylindole dihydrochloride 
was used to detect viable cells. The identification and 
enumeration of CTCs were performed with the use of the 
CellTracks Analyzer II, a semi-automated fluorescence-
based microscopy system that permits computer-generated 
reconstruction of cellular images. CTCs were defined as 
nucleated cells lacking CD45 and expressing cytokeratin. 
All positive samples were reviewed by two independent 
observers. For each CellSearch Epithelial Cell Kit, 
calculated for 15 patient samples, a test sample with a 
defined number of breast cancer cells was evaluated as a 
positive control. 
Bruneck cohort
Breast cancer patients in the Bruneck cohort 
were composed of patients with ER/PR negative breast 
cancer, ER/PR positive breast cancer, which had received 
tamoxifen but had stopped it when blood was withdrawn 
and a small group of ER/PR positive breast cancer, which 
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still received tamoxifen when blood was withdrawn. 
There was no difference in RANKL/OPG changes among 
these groups suggesting that the observed changes occur 
independent of anti-hormone therapy. All data in females 
and males were corrected for age, sex, body mass index, 
menopausal state, smoking, alcohol consumption, social 
status, physical activity, diabetes mellitus, creatinine levels 
and medication such as glucocorticoids and, importantly, 
hormone replacement therapy. For recruitment details in 
the prospective population-based Bruneck Study see refs. 
[28, 29]. A total of 15 subjects with cancer at baseline were 
excluded (three of them had a breast cancer). Of the 894 
subjects eligible, 748 remained free of cancer during the 
15-year follow-up between 1990 and 2005, 19 developed 
breast cancer, 16 developed prostate cancers, and 89 non-
breast cancers (all malignancies except for squamous-cell 
skin cancer). Cancer status was ascertained by the patient’s 
self-report and medical records. Tumors were obligatorily 
confirmed by histology. The situation in Bruneck is unique 
in that the hospital houses the only radiological facility 
and pathological laboratory in the whole region. 
Serum RANKL, OPG, and hormone measurements
Serum samples were immediately frozen and stored 
and transferred at -80°C before use. Matched case and 
control samples were handled identically and were assayed 
in random order. Laboratory personnel were unaware of 
the case-control status during all assays. Serum levels of 
progesterone were measured using a chemiluminescent 
immunoassay (with an Elecsys 2010 autoanalyzer, 
Roche Diagnostics). According to the manufacturer 
both intra- and inter-assay coefficients of variation were 
lower than 10% with detection limits of 0.095 nmol/l 
for progesterone. Serum levels of soluble RANKL and 
OPG were measured using a sandwich and competitive 
enzyme immunoassay (Biomedica, Vienna, Austria) as 
previously reported. According to the manufacturer, both 
the intra- and inter-assay coefficients of variation were 
lower than 10% with detection limits of 0.14 pmol/L for 
OPG and 0.08 pmol/L for soluble RANKL. Details on the 
measurement of OPG, free RANKL, and progesterone via 
ELISA have been reported for the Bruneck cohort [28, 29].
Statistical analysis
For analysis of the Bruneck cohort, statistical 
calculations were performed using the SPSS 15.0 and 
BMDP software packages. Concentrations of OPG 
and RANKL, and the RANKL/OPG ratio were loge-
transformed to approximate a normal distribution. 
Variable levels prior to and after cancer manifestation 
were compared with the paired t-test. Changes of variable 
levels among subjects with incident breast cancer, 
subjects with new-onset non-breast cancer and those 
who remain free of neoplastic disease were compared 
by means of general linear models (GLM) for repeated 
measurements. The same analyses were performed for 
male subjects. To account for the varying time intervals 
and to eliminate potential effects of ageing, all OPG and 
RANKL measurements were adjusted to baseline age of 
given individuals by linear regression techniques. Cox 
proportional hazard models were used to assess whether 
baseline levels of OPG and RANKL or the RANKL/OPG 
were independent risk predictors for the manifestation 
of breast, prostate, and non-breast/non-prostate cancer. 
Subjects who developed cancer were censored with 
respect to subsequent follow-up. Proportional hazard 
assumptions were confirmed by testing each variable with 
an interaction for time (Cox models with time-dependent 
covariates). Sensitivity analyses excluded subjects who 
received a cancer diagnosis within three years after 
baseline and yielded virtually identical results for all 
computations specified above. All reported P values are 
two-sided. 
For the UKCTOCS studies and SUCCESS trial, 
statistical analyses were conducted with the use of 
R software, version 2.11.1. To compare univariate 
distributions standard boxplots were utilized with 
0.25, 0.5 and 0.75 quantiles standing for box bottom, 
horizontal line and box top, and samples extremes for 
whiskers, to test difference between distributions Mann 
Whitney U test (Wilcoxon test) has been used. To stratify 
the risk for women with high progesterone Odds ratios 
and 95% confidence intervals were calculated through 
the conductance of logistic regression analyses for the 
categorical values. One tertile (1st for RANKL and 3rd 
otherwise) was referred as a reference value and Odds 
Ratios (ORs) of two other tertiles have been calculated 
with respect to the reference value. These ORs have been 
considered separately for cases with time to diagnosis 
more than 1 year and less, and accompanied with the 
corresponding confidence interval (CI) and P Value of the 
hypothesis that OR is different from one.
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